

Last day of trading in Peptonic paid subscribed shares

Stockholm, January 18th, 2016 - Peptonic Medical AB (publ) ("Peptonic Medical" or the "Company") – a company developing pharmaceutical products based on oxytocin - recently conducted a rights issue and a private placement. A total of 9 732 452 new shares were issued through the issues. Wednesday, January 20, 2016 is the last day of trading in the paid subscribed shares and the stop day is on Friday, January 22, 2016.

A total of 9 732 452 new shares have been registered with Bolagsverket (the Swedish Companies Registration Office) and the total number of shares in Peptonic Medical after the rights issue amounts to 19 174 412 shares and the share capital amounts to SEK 1 917 441.20.

For further information, please contact:

Johan Inborr, CEO
Phone: +46 708 853 893
E-mail: johan.inborr@peptonicmedical.se

About Peptonic Medical AB (publ)

Peptonic Medical AB (publ) is an innovative Swedish pharmaceutical company developing oxytocin based products e.g. for the treatment of menopausal symptoms, such as vaginal atrophy. Oxytocin has a long history of safe medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women. Peptonic Medical AB (publ)'s mission is to develop safe and effective drugs based on oxytocin.